Type i and type II Fc receptors regulate innate and adaptive immunity

Nature Immunology

Volumn 15, Issue 8, 2014, Pages 707-716

  Pincetic, Andrew ^a   Bournazos, Stylianos ^a   Dilillo, David J ^a   Maamary, Jad ^a   Wang, Taia T ^a   Dahan, Rony ^a   Fiebiger, Benjamin Maximillian ^a   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CANCER ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; TYPE I FC RECEPTOR; TYPE II FC RECEPTOR; UNCLASSIFIED DRUG; VACCINE;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANTIBODY DEPENDENT ENHANCEMENT; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL SELECTION; CRYSTAL STRUCTURE; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; VACCINATION;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANTIBODIES; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; GLYCOSYLATION; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; NEOPLASMS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IGG; VACCINATION;

EID: 84904627207     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2939     Document Type: Review

References (105)

1. Bournazos, S., Chow, S.K., Abboud, N., Casadevall, A. & Ravetch, J.V. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J. Clin. Invest. 124, 725-729 (2014).
2. DiLillo, D.J., Tan, G.S., Palese, P. & Ravetch, J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143-151 (2014).
3. Nimmerjahn, F. & Ravetch, J.V. Fc receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47 (2008).
4. Nimmerjahn, F. & Ravetch, J.V. Antibody-mediated modulation of immune responses. Immunol. Rev. 236, 265-275 (2010).
5. Anthony, R.M. & Ravetch, J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30, S9-S14 (2010).
6. Bournazos, S., Woof, J.M., Hart, S.P. & Dransfield, I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin. Exp. Immunol. 157, 244-254 (2009).
7. Sondermann, P., Pincetic, A., Maamary, J., Lammens, K. & Ravetch, J.V. General mechanism for modulating immunoglobulin effector function. Proc. Natl. Acad. Sci. USA 110, 9868-9872 (2013).
8. Nimmerjahn, F. & Ravetch, J.V. Fc-receptors as regulators of immunity. Adv. Immunol. 96, 179-204 (2007).
9. Nimmerjahn, F. & Ravetch, J.V. FcRs in health and disease. Curr. Top. Microbiol. Immunol. 350, 105-125 (2011).
10. Ravetch, J.V. & Bolland, S. IgG Fc receptors. Annu. Rev. Immunol. 19, 275-290 (2001).
11. Smith, K.G. & Clatworthy, M.R. FcRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10, 328-343 (2010).
12. Kimberly, R.P. et al. Diversity and duplicity: human Fc receptors in host defense and autoimmunity. Immunol. Res. 26, 177-189 (2002).
13. Takai, T. Fc receptors and their role in immune regulation and autoimmunity. J. Clin. Immunol. 25, 1-18 (2005).
14. Jefferis, R. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 526, 159-166 (2012).
15. Narciso, J.E. et al. Analysis of the antibody structure based on high-resolution crystallographic studies. N. Biotechnol. 28, 435-447 (2011).
16. Nimmerjahn, F. & Ravetch, J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
17. Krapp, S., Mimura, Y., Jefferis, R., Huber, R. & Sondermann, P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325, 979-989 (2003).
18. Teplyakov, A., Zhao, Y., Malia, T.J., Obmolova, G. & Gilliland, G.L. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface. Mol. Immunol. 56, 131-139 (2013).
19. Garman, S.C., Wurzburg, B.A., Tarchevskaya, S.S., Kinet, J.P. & Jardetzky, T.S. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature 406, 259-266 (2000).
20. Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-FcRIII complex. Nature 406, 267-273 (2000).
21. Davies, A.M. et al. Structural determinants of unique properties of human IgG4-Fc. J. Mol. Biol. 426, 630-644 (2014).
22. Bruhns, P. et al. Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716-3725 (2009).
23. Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
24. Lux, A. & Nimmerjahn, F. Impact of differential glycosylation on IgG activity. Adv. Exp. Med. Biol. 780, 113-124 (2011).
25. Shields, R.L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733-26740 (2002).
26. Scherer, H.U. et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 62, 1620-1629 (2010).
27. van de Geijn, F.E. et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res. Ther. 11, R193 (2009).
28. Shinzaki, S. et al. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am. J. Gastroenterol. 103, 1173-1181 (2008).
29. Tomana, M., Schrohenloher, R.E., Koopman, W.J., Alarcon, G.S. & Paul, W.A. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum. 31, 333-338 (1988).
30. Ferrara, C. et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA 108, 12669-12674 (2011).
31. Borrok, M.J., Jung, S.T., Kang, T.H., Monzingo, A.F. & Georgiou, G. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem. Biol. 7, 1596-1602 (2012).
32. Albert, H., Collin, M., Dudziak, D., Ravetch, J.V. & Nimmerjahn, F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl. Acad. Sci. USA 105, 15005-15009 (2008).
33. Barb, A.W. & Prestegard, J.H. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat. Chem. Biol. 7, 147-153 (2011).
34. Wormald, M.R. et al. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 36, 1370-1380 (1997).
35. Anthony, R.M. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373-376 (2008).
36. Anthony, R.M., Wermeling, F., Karlsson, M.C. & Ravetch, J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA 105, 19571-19578 (2008).
37. Hess, C. et al. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J. Clin. Invest. 123, 3788-3796 (2013).
38. Borthakur, S., Andrejeva, G. & McDonnell, J.M. Basis of the intrinsic flexibility of the C3 domain of IgE. Biochemistry 50, 4608-4614 (2011).
39. Dhaliwal, B. et al. Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcepsilonRI. Proc. Natl. Acad. Sci. USA 109, 12686-12691 (2012).
40. Selman, M.H. et al. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol. Cell. Proteomics 11, M111.014563 (2012).
41. Espy, C. et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). Arthritis Rheum. 63, 2105-2115 (2011).
42. Oefner, C.M. et al. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J. Allergy Clin. Immunol. 129, 1647-1655 (2012).
43. Diaz de Stahl, T. & Heyman, B. IgG2a-mediated enhancement of antibody responses is dependent on FcR+ bone marrow-derived cells. Scand. J. Immunol. 54, 495-500 (2001).
44. Kalergis, A.M. & Ravetch, J.V. Inducing tumor immunity through the selective engagement of activating Fc receptors on dendritic cells. J. Exp. Med. 195, 1653-1659 (2002).
45. Sutterwala, F.S., Noel, G.J., Clynes, R. & Mosser, D.M. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J. Exp. Med. 185, 1977-1985 (1997).
46. Boruchov, A.M. et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115, 2914-2923 (2005).
47. Dhodapkar, K.M. et al. Selective blockade of inhibitory Fc receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. USA 102, 2910-2915 (2005).
48. Blank, U., Launay, P., Benhamou, M. & Monteiro, R.C. Inhibitory ITAMs as novel regulators of immunity. Immunol. Rev. 232, 59-71 (2009).
49. Stuart, L.M. & Ezekowitz, R.A. Phagocytosis: elegant complexity. Immunity 22, 539-550 (2005).
50. Swanson, J.A. & Hoppe, A.D. The coordination of signaling during Fc receptor-mediated phagocytosis. J. Leukoc. Biol. 76, 1093-1103 (2004).
51. Regnault, A. et al. Fc receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189, 371-380 (1999).
52. Dhodapkar, K.M., Krasovsky, J., Williamson, B. & Dhodapkar, M.V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195, 125-133 (2002).
53. Schuurhuis, D.H. et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol. 176, 4573-4580 (2006).
54. Desai, D.D. et al. Fc receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J. Immunol. 178, 6217-6226 (2007).
55. Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677-686 (2004).
56. Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H. & Lambrecht, B.N. The function of Fc receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14, 94-108 (2014).
57. Jackson, S.M., Wilson, P.C., James, J.A. & Capra, J.D. Human B cell subsets. Adv. Immunol. 98, 151-224 (2008).
58. Fujiwara, H. et al. The absence of IgE antibody-mediated augmentation of immune responses in CD23-deficient mice. Proc. Natl. Acad. Sci. USA 91, 6835-6839 (1994).
59. Pearse, R.N. et al. SHIP recruitment attenuates FcRIIB-induced B cell apoptosis. Immunity 10, 753-760 (1999).
60. Tew, J.G., Wu, J., Fakher, M., Szakal, A.K. & Qin, D. Follicular dendritic cells: beyond the necessity of T-cell help. Trends Immunol. 22, 361-367 (2001).
61. Barrington, R.A., Pozdnyakova, O., Zafari, M.R., Benjamin, C.D. & Carroll, M.C. B lymphocyte memory: role of stromal cell complement and FcRIIB receptors. J. Exp. Med. 196, 1189-1199 (2002).
62. Ravetch, J.V. & Carroll, M.C. in Molecular Biology of B Cells (eds. Honjo, T., Alt, F.W. & Neuberger, M.S.) 275-287 (Elsevier, 2004).
63. Ravetch, J.V. & Nussenzweig, M. Killing some to make way for others. Nat. Immunol. 8, 337-339 (2007).
64. Xiang, Z. et al. FcRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8, 419-429 (2007).
65. González, D. et al. Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. Int. J. Infect. Dis. 9, 280-285 (2005).
66. Kliks, S.C., Nimmanitya, S., Nisalak, A. & Burke, D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38, 411-419 (1988).
67. Kliks, S. Antibody-enhanced infection of monocytes as the pathogenetic mechanism for severe dengue illness. AIDS Res. Hum. Retroviruses 6, 993-998 (1990).
68. Duerr, A. et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J. Infect. Dis. 206, 258-266 (2012).
69. Monsalvo, A.C. et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat. Med. 17, 195-199 (2011).
70. Guihot, A. et al. Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection. Am. J. Respir. Crit. Care Med. 189, 1240-1249 (2014).
71. Ubol, S. & Halstead, S.B. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin. Vaccine Immunol. 17, 1829-1835 (2010).
72. El Bakkouri, K. et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186, 1022-1031 (2011).
73. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
74. Hessell, A.J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007).
75. Abboud, N. et al. A requirement for FcR in antibody-mediated bacterial toxin neutralization. J. Exp. Med. 207, 2395-2405 (2010).
76. Tedder, T.F., Baras, A. & Xiu, Y. Fc receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin. Immunopathol. 28, 351-364 (2006).
77. Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood 99, 754-758 (2002).
78. Weng, W.K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003).
79. Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443-446 (2000).
80. Uchida, J. et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659-1669 (2004).
81. Musolino, A. et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26, 1789-1796 (2008).
82. Varchetta, S. et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 67, 11991-11999 (2007).
83. Bibeau, F. et al. Impact of FcRIIa-FcRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27, 1122-1129 (2009).
84. Smith, P., DiLillo, D.J., Bournazos, S., Li, F. & Ravetch, J.V. Mouse model recapitulating human Fc receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109, 6181-6186 (2012).
85. Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101-1110 (2014).
86. Li, F. & Ravetch, J.V. Inhibitory Fc receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030-1034 (2011).
87. White, A.L. et al. Interaction with FcRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187, 1754-1763 (2011).
88. Xu, Y. et al. FcRs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J. Immunol. 171, 562-568 (2003).
89. Wilson, N.S. et al. An Fc receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19, 101-113 (2011).
90. Li, F. & Ravetch, J.V. A general requirement for FcRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle 11, 3343-3344 (2012).
91. Chuntharapai, A. et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166, 4891-4898 (2001).
92. Li, F. & Ravetch, J.V. Antitumor activities of agonistic anti-TNFR antibodies require differential FcRIIB coengagement in vivo. Proc. Natl. Acad. Sci. USA 110, 19501-19506 (2013).
93. Bulliard, Y. et al. Activating Fc receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210, 1685-1693 (2013).
94. Simpson, T.R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695-1710 (2013).
95. Imbach, P. et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1, 1228-1231 (1981).
96. Anthony, R.M., Wermeling, F. & Ravetch, J.V. Novel roles for the IgG Fc glycan. Ann. NY Acad. Sci. 1253, 170-180 (2012).
97. Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513-533 (2008).
98. Debré, M. et al. Infusion of Fc fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945-949 (1993).
99. Schwab, I. et al. Broad requirement for terminal sialic acid residues and FcRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. Eur. J. Immunol. 44, 1444-1453 (2014).
100. Crow, A.R. et al. IVIg-mediated amelioration of murine ITP via FcRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102, 558-560 (2003).
101. Crow, A.R., Song, S., Semple, J.W., Freedman, J. & Lazarus, A.H. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br. J. Haematol. 115, 679-686 (2001).
102. Tackenberg, B. et al. Impaired inhibitory Fc receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl. Acad. Sci. USA 106, 4788-4792 (2009).
103. Portman, M.A., Wiener, H.W., Silva, M., Shendre, A. & Shrestha, S. DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease. Pediatr. Rheumatol. Online J. 11, 32 (2013).
104. Crow, A.R., Song, S., Semple, J.W., Freedman, J. & Lazarus, A.H. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg Blood 109, 155-158 (2007).
105. Schwab, I., Biburger, M., Kronke, G., Schett, G. & Nimmerjahn, F. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur. J. Immunol. 42, 826-830 (2012).